Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-16
2005-08-16
Li, Q. Janice (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093210, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
06930094
ABSTRACT:
The present invention relates to the use of tissue factor for influencing blood vessel formation, particularly for activating blood vessel formation, above all for wound healing.
REFERENCES:
patent: 5100792 (1992-03-01), Sanford et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6120799 (2000-09-01), McDonald et al.
patent: WO 94/05328 (1997-03-01), None
patent: WO 98/34634 (1998-08-01), None
Robbins et al, Pharmcol Ther 1998;80:35-47.
Miller et al, Hum Gene Ther May 1997;8:803-15.
TW Dubensky, Jr. et al., Journal of Virology,“Sindbis Virus DNA-Based Expression Vectors:Utility for In Vitro and In Vivo Gene Transfer,” Jan. 1996, vol. 70, No. 1, pp. 508-519.
IM Verma et al., Nature, “Gene therapy-promises, problems and prospects,”Sep. 1997, vol. 389, pp. 239-242.
F Levine et al., Molecular Medicine Today,“Towards gene therapy of diabetes mellitus,” Apr. 1999, vol. 5, pp. 165-171.
Judah Folkman, “Tumor Angiogenesis and Tissue Factor”, Nature Medicine, vol. 2, No. 2, Feb. 1996, pp. 167-168, Nature Publishing Group, New York, New York, USA.
Vickie Brower, “Genentech Enlightens other Angiogenesis Programs”, Nature Biotechnology, vol. 17, Apr. 1988, pp. 326-327, Nature Publishing Group, New York, New York, USA.
Nicola Semeraro et al., “Tissue Factor in Health and Disease”, Thrombosis and Haemostasis, vol. 78, No. 1, 1997, pp. 759-764, F.K. Schattauer Verlagsgesellschaft mbH, Stuttgart, Germany.
Banner, D.W. et al., “The crystal structure of the complex of blood coagulation factor Vlla with soluble tissue factor”, Nature, 1996, pp. 21-23, vol. 380, No. 6569, Nature Publishing Group, Hampshire, United Kingdom.
Bazan, J.F., “Structural design and molecular evolution of a cytokine receptor superfamily”, Proc. Natl. Acad. Sci. USA, 1990, pp. 6934-6938, vol. 87, National Academy of Sciences, Washington, D.C., USA.
Camerer, E. et al., “Cell Biology of tissue factor, the principal initiator of blood coagulation”, Thromb Res, 1996, p. 1-41, vol. 81, No. 1, Elsevier Science, London, United Kingdom.
Edgington, T.S. et al., “The structural biology of expression and function of tissue factor” Thromb Res, 1991, pp. 67-69, vol. 66, No. 1, Elsevier Science, London, United Kingdom.
Gibbs, C.S. et al., “Identification of the Factor Vlla binding site on Tissue Factor by homologous loop swap and alanine scanning mutagenesis”, Biochemistry, 1994, pp. 14003-14010, vol. 33, American Chemical Society, Washington, D.C., USA.
Harlos, K. et al., “Crystal structure of the extracellular region of human tissue factor” Nature, 1994, pp. 662-666, vol. 370, No. 6491, Nature Publishing Group, Hampshire, United Kingdom.
Hasselbacher, C.A. et al., “Environments of the four typtophans in the extracellular domain of human tissue factor: comparison of results from absorption and fluorescence difference spectra of tryptophan replacement mutants with crystal structure of the wild-type protein”, Biophys J, 1995, pp. 20-29, vol. 69, No. 1, Stanford University Libraries'HighWire Press, Stanford, CA, USA.
Huang, X. et al., “Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature”, Science, 1997, pp. 547-550, vol. 275, No. 5299, Association for the Advancement of Science with the assistance of Stanford University Libraries'HighWire Press, Stanford CA, USA.
Mackman, N, “Regulation of the Tissue Factor gene” FASEB J, 1995, pp. 883-639, vol. 9, The Federation of American Societies for Experimental Biology, Bethesda, MD, USA.
Mackman, N. et al., “Complete sequence of the human Tissue Factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade”, Biochemistry, 1989, pp. 1755-1762, vol. 28, American Chemical Society, Washington, D.C., USA.
Muller, Y.A. et al., “The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution”, J Mol Biol, 1996, pp. 144-159, vol. 256, No. 1, Academic Press, San Diego, CA, USA.
O'Brien, D.P. et al., “Structural requirements for the interaction between tissue factor and factor VII: characterisation of chymotrypsin-derived tissue factor polypeptides” Biochem J, 1993, pp. 7-12, vol. 292, Portland Press, Portland, OR, USA.
Paborsky, L.R. et al., “Lipid association, but not the transmembrane domain, is required for Tissue Factor activity”, The Journal of Biological Chemistry, 1991, pp. 21911-21916, vol. 266, No. 32, American Society for Biochemistry and Molecular Biology, Bethesda, MD, USA.
Ruf, W. et al., “Two sites in the tissue factor extracellular domain mediate the recognition of the ligand factor Vlla”, Proc Natl Acad Sci USA, 1991, pp. 8430-8434, vol. 88, No. 19, National Academy of Sciences, Washington, D.C., USA.
Ruf, W. et al., “Antibody mapping of tissue factor implicates two different exon-encoded regions in function”, Biochem J, 1991, pp. 729-733, vol. 278, Portland Press, Portland, OR, USA.
Ruf, W. et al., “Phospholipid-independent and dependent interactions required for Tissue Factor Receptor and cofactor function”, Journal of Biol Chem, 1991, pp. 2158-2166, vol. 266, No. 4, American Society for Biochemistry and Molecular Biology, Bethesda, MD, USA.
Ruf, W. et al., “Mutational mapping of functional residues in tissue factor identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain”, Biochemistry, 1994, pp. 1565-1572, vol. 33, No. 6, American Chemical Society, Washington, D.C., USA.
Schullek, J.R. et al., “Key ligand interface residues in tissue factor contribute independently to factor Vlla binding”, J Biol Chem, 1994, pp. 19399-19403, vol. 269, No. 30, American Society for Biochemistry and Molecular Biology, Bethesda, MD, USA.
Spicer, EK. et al., “Isolation of cDNA clones coding for human tissue factor primary structure of the protein and cDNA”, Proc Natl Acad Sci USA, 1987, pp. 5148-5152, vol. 84, No. 15, National Academy of Sciences, Washington, D.C., USA.
Carmeliet et al., 1996, “Role of tissue factor in embryonic blood vessel development,”Nature 383(6595):73-75.
Contrino et al., 1996, “In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease,”Nat. Med. 2(2):209-215.
Nakagawa et al., 1998, “The angiogenic effect of tissue factor on tumors and wounds,”Semin. Thromb. Hemost. 24(3):207-210.
Scarpati et al., 1987, “Human tissue factor: cDNA sequence and chromosome localization of the gene,”Biochemistry 26(17):5234-5238.
Shoji et al., 1996, “Tissue factor regulates the expression of vascular endothelial growth factor (VEGF) in vitro and angiogenesis in vivo,”Blood 88(10 Suppl 1):514a.
Shoji et al., 1997, “Molecular mechanisms linking thrombosis and angiogenesis in cancer,”Trends in Cardiovascular Medicine 7(2):52-59.
Toomey, et al., 1996, “Targeted disruption of the murine tissue factor gene results in embryonic lethality,”Blood 88(5):1583-1587.
Wilcox et al., 1989, “Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque,”Proc. Natl. Acad. Sci. U.S.A. 86(8):2839-2843.
Zhang et al., 1994, “Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice,”J. Clin. Invest 94(3):1320-1327.
Bellon et al., “Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial.”, Hum Gene Ther., 1997, 8(1):15-25; Mary Ann Liebert, Inc., Larchmont, New York (Abstract only).
Crombleholme, “Adenoviral-mediated gene transfer in wound healing.”, Wound Repair Regen., Nov.-Dec., 2000; 8(6):460-72; Blackwell Publishing, Oxford, Eng
Nakagawa Katsumi
Nawroth Peter
Zhang Youming
Burns Doane Swecker & Mathis L.L.P.
Li Q. Janice
Merckle GmbH
LandOfFree
Tissue factor for influencing blood vessel formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue factor for influencing blood vessel formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue factor for influencing blood vessel formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3517904